Description
Pharmaceutical Glass Packaging Market Analysis
The global pharmaceutical glass packaging market is anticipated to surpass USD 13.5 billion by 2027 and is going to witness the highest CAGR of 6.9% by the end of 2026. Glass packaging is the safest way of packaging as the glass does not get contaminated and cause reactions.
Additionally, as compared to conventional plastic packaging, glass material can be recycled and reused and it has already exhibited various packaging-friendly properties such as sterility, chemical inertness, malleability, and water resistance.
The global pharmaceutical glass packaging market is anticipated to exhibit an incredible market expansion having the largest market value of USD 7.6 billion in 2020. The rising need for packaging, technological innovations, and demand for extending the shelf life of pharmaceutical products and other factors are expected to propel the overall growth of the global pharmaceutical industry.
However, the major market restraint is the increasing demand for plastic packaging as it has properties such as safety to handle and lightweight. Furthermore, the rising need for pharmaceutical glass packaging in developing countries is set to offer lucrative growth opportunities for the players operating in the global pharmaceutical glass packaging market during the review period.
Pharmaceutical Glass Packaging Market Segmentation
The global pharmaceutical glass packaging market has been classified into type, material, application, and region.
In terms of product type, the global pharmaceutical glass packaging market has been classified into vials, bottles & jars, cartridges & syringes, and ampoules. Based on material type, the pharmaceutical glass packaging market has been divided into type I, type II, and Type III. Based on application, the global market has been categorized into generic drugs, branded drugs, and biological drugs.
Pharmaceutical Glass Packaging Market Regional Analysis
The region-specific analysis of the global pharmaceutical glass packaging market is studied across North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America is one of the noticeable regions for the pharmaceutical glass packaging market. The area has seen expanded interests in R&D and item development all things considered. Rigid guidelines and approaches in the US and Canada expanded utilization of medications, and quick development of the pharmaceutical area are the components driving the interest for pharmaceutical glass packaging in the locale.
The US is the major market contributor to the global glass packaging market in North America.
In the US, the pharmaceutical glass packaging industry is seeing quick development. With the extending market for drugs, the interest in glass packaging increments persistently in the pharmaceutical business. Developing medical services spending is boosting the development of the pharmaceutical glass packaging market in the country.
Major Players of Pharmaceutical Glass Packaging Market
The leading players of the global pharmaceutical glass packaging market include Schott AG (Germany), Nipro Corporation (Japan), Piramal Glass (Mumbai), Sisecam Group (Tuzla, TR), Owens-Illinois Inc. (US) in 2019.
Additionally, Gerresheimer AG (Germany), SGD Pharma (France), Bormioli Pharma S.p. (Italy), Ardagh Group S.A.(Luxembourg), West Pharmaceutical Services Inc. (US), and StoelzleOberglasGmbh (Austria) are developing as major players.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
E-Glass Market to Surge at 3.33% CAGR, which is anticipated to reach USD 39.4 billion by 2030.
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 EXECUTIVE SUMMARY
1.1.1 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT
1.1.2 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE
1.1.3 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION
1.1.4 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
3.6 LIST OF ASSUMPTIONS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 EXTENDING THE SHELF LIFE OF PRODUCTS
4.2.2 TECHNOLOGICAL DEVELOPMENTS IN PHARMACEUTICAL GLASS PACKAGING
4.2.3 INCREASING DEMAND FROM THE PHARMACEUTICAL INDUSTRY
4.2.4 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINT
4.3.1 GROWING DEMAND FOR PLASTIC PACKAGING
4.3.2 RESTRAINT IMPACT ANALYSIS
4.4 OPPORTUNITY
4.4.1 INCREASING DEMAND IN EMERGING ECONOMIES
4.5 REGULATORY FRAMEWORK
4.5.1 ASPECTS OF PACKAGING
4.5.1.1 GENERAL CONSIDERATIONS
4.5.1.2 COMPLIANCE
4.5.2 PACKAGING MATERIALS AND CLOSURES
4.5.3 QUALITY ASSURANCE ASPECTS OF PACKAGING
4.5.3.1 GENERAL CONSIDERATIONS
4.5.3.2 QUALITY CONTROL
4.5.3.2.1 SAMPLING
4.5.3.2.2 TESTING PROGRAMME
4.5.3.3 INSPECTION AND AUDIT
4.5.3.3.1 RULES
4.5.3.3.2 AUDITS OF SUPPLIERS
4.5.4 PROTECTION OF THE ENVIRONMENT
4.5.4.1 PACKAGING WASTE
4.5.4.2 WASTE POLICIES
4.6 PROFIT MARGIN ANALYSIS
4.7 RELATION BETWEEN CAPACITY UTILIZATION RATE & PRODUCT PRICES
4.7.1 LOW UTILIZATION
4.7.2 FULL UTILIZATION
4.7.3 OVER-UTILIZATION
4.8 CAPAPCITY UTILISATION ANALYSIS
4.8.1 AVERAGE CAPACITY UTILISATION RANGE OF PROMINENT PLAYERS, 2014-2019
4.8.2 ESTIMATED PLANNED AND FORECASTED CAPACITY EXPANSION BY PROMINENT PLAYERS
4.9 COVID-19 IMPACT ANALYSIS
4.9.1 ECONOMIC IMPACT
4.9.1.1 IMPACT ON THE OVERALL PACKAGING INDUSTRY
4.9.2 IMPACT ON PRODUCTION
4.9.3 IMPACT ON GLASS PACKAGING MARKET
4.9.3.1 IMPACT ON SUPPLY CHAIN
4.9.3.2 IMPACT ON RAW MATERIAL
4.9.3.3 CASH FLOW CONSTRAINTS
4.9.4 IMPACT ON WORLD TRADE
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 RAW MATERIAL SUPPLY
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION CHANNELS
5.1.4 END USERS
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
6 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT
6.1 OVERVIEW
6.1.1 VIALS
6.1.2 BOTTLES & JARS
6.1.3 CARTRIDGES & SYRINGES
6.1.4 AMPOULES
7 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE
7.1 OVERVIEW
7.1.1 TYPE I
7.1.2 TYPE II
7.1.3 TYPE III
8 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION
8.1 OVERVIEW
8.1.1 GENERIC DRUGS
8.1.2 BRANDED DRUGS
8.1.3 BIOLOGICAL DRUGS
9 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 MEXICO
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 REST OF ASIA-PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 ARGENTINA
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 UAE
9.6.2 SAUDI ARABIA
9.6.3 SOUTH AFRICA
9.6.4 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 COMPETITIVE OVERVIEW
10.3 MARKET SHARE ANALYSIS
10.4 COMPETITIVE BENCHMARKING
10.5 GERRESHEIMER AG: LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCHES/SERVICE DEPLOYMENTS
10.6.2 EXPANSIONS
10.6.3 MERGERS & ACQUISITIONS/INVESTMENTS
10.6.4 PARTNERSHIPS/CONTRACTS & AGREEMENTS
11 COMPANY PROFILES
11.1 GERRESHEIMER AG
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 NIPRO CORPORATION
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 SCHOTT AG
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 SGD PHARMA
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.5 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.6 BORMIOLI PHARMA S.P.A.
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.7 ARDAGH GROUP S.A.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 WEST PHARMACEUTICAL SERVICES, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 PIRAMAL ENTERPRISES LIMITED
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 STOELZLE OBERGLAS GMBH
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.11 ARAB PHARMACEUTICAL GLASS CO.
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.12 ŞİŞECAM GROUP
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCTS OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 SWOT ANALYSIS
11.12.6 KEY STRATEGIES
11.13 OWENS-ILLINOIS INC.
11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL OVERVIEW
11.13.3 PRODUCTS OFFERED
11.13.4 KEY DEVELOPMENTS
11.13.5 SWOT ANALYSIS
11.13.6 KEY STRATEGIES
11.14 BECTON, DICKINSON AND COMPANY
11.14.1 COMPANY OVERVIEW
11.14.2 FINANCIAL OVERVIEW
11.14.3 PRODUCTS OFFERED
11.14.4 KEY DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.14.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCE
